In addition to its individual functions, TTYH3 may also promote tumorigenesis by fusion with BRAF serine/threonine kinase (TTYH3-BRAF fusion protein) in glioblastoma, histiocytic sarcoma, and thyroid carcinoma 36-38. This evidence concerns the gene MARK2 and histiocytic sarcoma.